BPR: What is tranScrip planning at BIO International Boston?
We see BIO as one of the key industry meetings and will have a strong team in Boston this year, fostering our relationships with current clients and developing new ones with biotech and pharma alike.
Our team share a wealth of experience and knowledge, alongside operational skills, to help companies deliver on the complexities of the drug development process.
BPR: What impact will tranScrip’s recent acquisition of Real Regulatory have for the company and its clients?
The acquisition offers our clients unrivalled access to a breadth of regulatory expertise and skills, including development and post-approval activities, CMC and medical devices, providing the strategic insight and delivery support needed to achieve product success.
It also puts tranScrip in a better position to continue its growth and strengthen its multi-functional drug development teams across all phases of product lifecycle and different therapy areas.
BPR: There have been a number of recent new appointments at tranScrip, strengthening the clinical programme management and the senior leadership team. What do the appointments mean for the business?
We have been steadily building our team of experts across therapy and functional areas, as well as strengthening our leadership team to drive the growth of the business over the next few years.
The most recent appointment of Emma Chaffin as the VP, head of commercial strategy significantly expands our capabilities to cover commercial and portfolio management activities, an inherent part of the product lifecycle.
BPR: Any other new developments? What is next in the growth plan for tranScrip?
The industry is evolving rapidly. Our goal is to be at the forefront of the industry with our partners, harnessing our experience and network to drive forward future drug innovation and development.
We have ambitious plans for both organic growth and strategic acquisitions and I hope we will be able to share some exciting news later this year.
